Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02214147 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function
A Phase 1 study, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT02214147 is a Phase 1 study that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 36 participants.
The verdict
NCT02214147, a Phase 1 study, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of moderate or severe hepatic impairment on the single-dose pharmacokinetics of alisertib in adult participants with cancer.
Interventions
- DRUG Alisertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2014-08-21 |
| Est. Completion | 2016-07-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02214147
The ClinicalTrials.gov registry entry for NCT02214147 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Alisertib is the first listed.
NCT02214147 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02214147 about?
NCT02214147 is a clinical study titled "Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function". The purpose of this study is to evaluate the effect of moderate or severe hepatic impairment on the single-dose pharmacokinetics of alisertib in adult participants with cancer.
What is the current status of trial NCT02214147?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2014-08-21. Estimated completion is 2016-07-18.
What interventions are being tested in trial NCT02214147?
The interventions under investigation include: Alisertib (DRUG).
Who is sponsoring clinical trial NCT02214147?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.